American drug-maker Merck has agreed to let some companies produce its experimental COVID-19 pill.

    The move, announced Wednesday by a health organization supported by the United Nations, is aimed at helping people in poorer countries to get the drug.

    The Medicines Patent Pool, or MPP, said in a joint statement that the agreement will make the drug molnupiravir available "in 105 low- and middle-income countries." The drug also will need approval from local health officials.

    Under the agreement, the health agency is permitted to license qualified companies to manufacture the antiviral drug. Merck and its partners, Ridgeback Biotherapeutics and Emory University in Georgia, will not receive money for sales of molnupiravir as long as the World Health Organization considers COVID-19 a "Public Health Emergency of International Concern."
    根据该协议,该卫生机构获准授权合格公司生产这种抗病毒药物。只要世卫组织将新冠肺炎视为“国际关注的突发公共卫生事件”,默沙东公司及其合作伙伴Ridgeback Biotherapeutics以及乔治亚州的埃默里大学就不会收到莫努匹韦的销售款项。

    Pill awaiting approval

    In early October, Merck reported that its experimental pill reduced hospitalizations and deaths by half among people infected with COVID-19 in a drug trial. The company is asking health officials in the United States and around the world to approve the pill for treatment of coronavirus infections.

    Pfizer and Roche, two other drug companies, are also working on similar COVID-19 pills. But molnupiravir could be the first pill approved for the treatment of COVID-19. A pill can be taken at home and is easier to send around the world. All other approved COVID-19 treatments must be injected by healthcare workers.

    Charles Gore is the Executive Director of MPP. He said early results of the drug were "compelling." Gore said the pill is an "important tool" to help deal with the current health crisis. He said he hoped the agreement will lead to others.

    The non-profit group Doctors Without Borders, also known as MSF, welcomed the agreement to share Merck's COVID-19 pill. But it said the license "doesn't go far enough."

    Yuanqiong Hu is a senior legal and policy adviser with MSF. She said the license does not include nearly half of the world's population in countries like Brazil and China. The two also have "strong, established capacity to produce and supply antiviral medicines."

    Hu noted the license would also limit "the production and supply of more affordable and available generic molnupiravir."

    Cheaper generic version

    Merck said earlier that it could produce 10 million treatments of the pill this year. The treatment requires two pills a day for five days. The U.S. has already purchased 1.7 million treatments at the cost of $700 each.

    The company is also working with several Indian companies to license cheaper, generic versions of molnupiravir for low- and middle-income countries. Researchers at Harvard University's T.H. Chan School of Public Health estimated that a generic version could cost less than $20 for each treatment.

    Last week, the Bill & Melinda Gates Foundation announced that it would spend up to $120 million to help develop generic versions of molnupiravir.
    上周,比尔和梅琳达·盖茨基金会宣布将斥资高达1.2 亿美元帮助开发莫努匹韦的仿制药。

    "To end this pandemic, we need to ensure that everyone, no matter where they live in the world, has access to life-saving health products," said Melinda French Gates, co-chair of the Gates Foundation, in a statement.

    I'm Jonathan Evans.